The B-cell lymphoma 2 (BCL-2) TR-FRET Assay Kit is designed to measure the inhibition of BCL-2 binding to its
ligａnd in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps,
making it especially suitable for high throughput screening applications. The assay procedure is straightforward
ａnd simple; a sample containing terbium-labeled donor, dye-labeled acceptor, BCL-2, peptide ligand, and an
inhibitor is incubated for 180 minutes. Then, the fluorescence intensity is measured using a fluorescence reader
capable of TR-FRET measurements.

Figure 1. Illustration of the assay principle: The Donor Terbium-labeled anti-His antibody binds to His-tagged BCL-2. The BCL-2 peptide ligａnd is labeled with biotin, which allows the dye-labeled streptavidin acceptor to bind to the BCL-2 peptide ligand. The TR-FRET signal is generated by proximity induced upon interaction of BCL-2 with the BCL-2 peptide ligand.

This product has been cited 3 times.